
|Videos|January 30, 2023
Relapse in Multiple Myeloma: Biochemical and Chemical
Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Related to this article

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5




